



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Aplaviroc hydrochloride

Cat. No.:	HY-17450A
CAS No.:	461023-63-2
Molecular Formula:	C ₃₃ H ₄₄ ClN ₃ O ₆
Molecular Weight:	614.17
Target:	CCR; HIV
Pathway:	GPCR/G Protein; Immunology/Inflammation; Anti-infection
Storage:	4°C, sealed storage, away from moisture
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (325.64 mM; Need ultrasonic)				
	H ₂ O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	1.6282 mL	8.1411 mL	16.2821 mL
		5 mM	0.3256 mL	1.6282 mL	3.2564 mL
10 mM		0.1628 mL	0.8141 mL	1.6282 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 12.5 mg/mL (20.35 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 12.5 mg/mL (20.35 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 12.5 mg/mL (20.35 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC ₅₀ s of 0.1-0.4 nM for HIV-1 _{Ba-L} , HIV-1 _{JRFL} and HIV-1 _{MOKW} .			
IC ₅₀ & Target	HIV-1 _{Ba-L} 0.4 nM (IC ₅₀)	HIV-1 _{JRFL} 0.1 nM (IC ₅₀)	HIV-1 _{MOKW} 0.2 nM (IC ₅₀)	CCR5
In Vitro	Aplaviroc exerts potent activity against three wild-type R5 HIV-1 strains (HIV-1 _{Ba-L} , HIV-1 _{JRFL} and HIV-1 _{MOKW}) with IC ₅₀ values of 0.1 to 0.4 nM. Aplaviroc is substantially more potent than two previously published CCR5 inhibitors, E921/TAK-779			

and AK671/SCH-C. Aplaviroc suppresses the infectivity and replication of two HIV-1_{MDR} variants, HIV-1_{MM} and HIV-1_{JSL}, at extremely low concentrations (IC₅₀ values of 0.4 to 0.6 nM). Aplaviroc binds to CCR5 with high affinity. The K_d values thus determined for Aplaviroc, E913, E921/TAK-779, and AK671/SCH-C are 2.9±1.0, 111.7±3.5, 32.2±9.6, and 16.0±1.5 nM, respectively. Aplaviroc potently blocks rgp120/sCD4 binding to CCR5 with an IC₅₀ value of 2.7 nM. These results suggest that the potent activity of Aplaviroc against R5 HIV-1 stems from its binding to ECL2B and/or its vicinity with high affinity, resulting in inhibition of gp120/CD4 binding to CCR5^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The concentration of Aplaviroc (AK602) reached the maximal concentration immediately after intraperitoneal administration and decreased rapidly^[2].

Aplaviroc (AK602, 60 mg/kg, bid, daily) suppresses R5 HIV-1 viremia in hu-PBMC-NOG mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	hu-PBMC-NOG mice ^[2] .
Dosage:	60 mg/kg.
Administration:	Single intraperitoneal administration, bid, daily.
Result:	The numbers of CD4 ⁺ cells/μL in saline-treated mice were significantly less than those of AK602-treated, ddl-treated, or uninfected mice.

REFERENCES

[1]. Maeda K, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol. 2004 Aug;78(16):8654-62.

[2]. Hirotomo Nakata, et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Virol. 2005 Feb;79(4):2087-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA